Le Lézard10d
AliveDx announces US FDA 510(k) submission for MosaiQ AiPlex® Celiac Disease (CD) multiplex microarray
Our CD microarray includes 5 markers in one panel for each patient, including the majority of autoantibodies recommended by the relevant clinical guidelines (ESsCD, ACG and ESPGHAN)* 2-5. The MosaiQ ...
Pharmabiz9d
AliveDx seeks US FDA 510(k) premarket approval for MosaiQ AiPlex CD multiplex microarray
AliveDx seeks US FDA 510(k) premarket approval for MosaiQ AiPlex CD multiplex microarray: Eysins, Switzerland Tuesday, February 11, 2025, 12:00 Hrs [IST] AliveDx, an established c ...
Morningstar10d
AliveDx announces US FDA 510(k) submission for MosaiQ AiPlex® Celiac Disease (CD) multiplex microarray
For Celiac Disease, the multiplex assay is designed to rapidly detect and identify up to 425 disease markers per hour. Seamless, microarray-internal calibration and quality control as well as ...
GEN18d
Measuring Intact (Full-length, Capped, Tailed) mRNA in a Single Assay: 5′CapQ
Figure 1. (Left) examples of flexible VaxArray microarray-based assay designs, with 5’CapQ assay schematic highlighted, (Center) a schematic of a single VaxArray microarray slide with 16 ...
GlobalData on MSN17d
AliveDx gains IVDR CE mark for MosaiQ AiPlex CTDplus assay
AliveDx’s CE mark for the systematic autoimmune rheumatic disease (SARD) assay marks its fifth approval in the past 18 months.